期刊文献+

艾灸预处理对阿尔茨海默病模型大鼠海马CA1区BDNF及其受体TrkB的影响 被引量:13

Effect of Moxibustion pretreatment on the expression of brain-derived neurotrophic factor and its receptor TrkB in hippocampus CA1 region of rats with Alzheimer′s disease
暂未订购
导出
摘要 目的探讨艾灸预处理防治阿尔茨海默病(AD)的作用机制。方法健康雄性SD大鼠40只,随机分为正常组、假手术组、模型组和预艾灸组。双侧海马一次性注射聚集态Aβ25~35制作AD模型,艾灸"百会"、"肾俞"、"足三里"进行防治,免疫组化SP法观察大鼠海马CA1区脑源性神经营养因子(BDNF)及其受体TrkB的表达及艾灸干预的影响。结果与正常组及假手术组比较,模型组大鼠海马CA1区BDNF及TrkB的表达明显下降,表现为阳性神经元平均灰度值明显上升(P<0.01);与模型组比较,预艾灸组大鼠海马CA1区BDNF及TrkB的表达明显增加,表现为阳性神经元平均灰度值明显下降(P<0.01)。结论预艾灸治疗可显著增加海马CA1区BDNF及TrkB的表达,从而改善脑内神经元的损伤,起到保护脑细胞的作用。 Objective To investigate the mechanism of Moxibustion pretreatment in prevention and cure of Alzheimer's disease (AD). Methods Rats were randomly divided into normal , sham, model and moxibustion pretreatment groups ( n = 10). AD rats were induced by injecting β-amyloid25-35 (Aβ325-35) into the double hippocampus. Baihui, Shenshu and Zusanli acupoints were used to prevent and cure AD by moxibustion. Brain-derived neurotrophic factor (BDNF) and its receptor TrkB in hippocampus CA1 zone of rats were detected by immunohistochemistry. Results Compared with normal and sham group, the expression of BDNF and its receptor TrkB in model group were significantly decreased (P 〈 0. 01 ). Compared with the model group, the expressions of BDNF and TrkB in moxibustion pretreatment group were significantly increased (P 〈 0. 01 ). Conclusions Moxibustion pretreatment could effectively increase the expressions of BDNF and TrkB in hippocampus CA1 zone, ameliorate the neuron injury of the brain and protect the brain cells.
机构地区 湖北中医药大学
出处 《中国老年学杂志》 CAS CSCD 北大核心 2012年第21期4663-4665,共3页 Chinese Journal of Gerontology
基金 湖北省教育厅科学技术研究项目(Q20101803) 武汉市科技局青年科技晨光计划项目(201150431126) 湖北中医药大学校级科研项目(中医院字〔2008〕192号)
关键词 阿尔茨海默病 艾灸预处理 BDNF TRKB Alzheimer's disease Moxibustion pretreatment Brain-derived neurotrophic(BDNF) TrkB
  • 相关文献

参考文献12

  • 1任汝静,陈生弟.阿尔茨海默病的治疗现状和展望[J].中国现代神经疾病杂志,2005,5(3):147-151. 被引量:10
  • 2Sramek JJ,Veroff AE,Cutler NR.Mild cognitive impairment:emerging therapeutics(J).Ann Pharmacother,2000;34(10):1179-88.
  • 3李芳,李光荣,满玉清.Aβ25-35双侧海马内注射痴呆模型大鼠空间学习记忆的改变[J].药物生物技术,2005,12(3):190-192. 被引量:13
  • 4Morimoto K,Yoshimi K,Tonohiro T,et al.Coinjection ofβ-amyloid with ibotenic acid induces synergistic loss of rat hippocampal neurons(J).Neuroscience,1998;84(2):479-87.
  • 5华兴邦,周浩良.大鼠穴位图谱的研制[J].实验动物与动物实验,1991(1):1-5. 被引量:1221
  • 6朱建华.老年性痴呆[J].江苏中医药,2004,25(10):12-14. 被引量:7
  • 7崔德芝,张恭新,朱振铎.老年性痴呆的中医理论探讨[J].山东中医杂志,2006,25(10):655-657. 被引量:34
  • 8Mctigue DM,Horner PJ,Stokes BT,et al.Neurotrophic-3 and brain-de-rived neurotrophic factor induce oligodendrocyte proliferation and myeli-nation of regenerating axons in the contused adult rat spinal cord(J).J Neurosci,1998;18(14):5354-65.
  • 9Mu JS,Li WP,Yao ZB,et al.Deprivation of endogenous brain derived neurotrophic factor results in impairment of spatial learning and memory in adult rats(J).Brain Res,1999;835(2):259-65.
  • 10Merlio JP,Ernfors P,Kokaia Z,et al.Increased production of the TrkBprotein tyrosine kinase receptor after brain insults(J).Neuron,1993;10(2):151-64.

二级参考文献33

  • 1[1]Wimo A, Winblad B. Economic aspects on drug therapy of dementia.Curr Pharm Des, 2004, 10:295-301.
  • 2[2]Jeffrey LC. Alzheimer's disease. N Engl J Med, 2004, 351:56-67.
  • 3[3]Winblad B, Jelic V. Long-term treatment of Alzheimer disease: efficacy and safety of acetylcholinesterase inhibitors. Alzheimer Dis Assoc Disord, 2004, 18 (Suppl 1):2-8.
  • 4[4]Courtney C, Farrell D, Gray R, et al. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet, 2004, 363:2105-2115.
  • 5[5]Tang XC, He XC, Bai DL. Huperzine A: a novel acetylcholinesterase inhibitor. Drugs Fut, 1999, 24:647-663.
  • 6[7]Rive B, Vercelletto M, Damier FD, et al. Memantine enhances autonomy in moderate to severe Alzheimer's disease. Int J Geriatr Psychiatry, 2004, 19:458-464.
  • 7[8]Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence.JAMA,2005, 293:596-608.
  • 8[9]Hock C, Maddalena A, Raschig A, et al. Treatment with the selective muscarinic m1 agonist talsaclidine decreases cerebrospinal fluid levels of A beta 42 in patients with Alzheimer's disease. Amyloid,2003, 10:1-6.
  • 9[10]Wong GT, Manfra D, Poulet FM, et al. Chronic treatment with the gamma-secretase inhibitor LY-411, 575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem, 2004, 279:12876-12882.
  • 10[11]Andersona JJ, Holtza G, Baskin PP, et al. Reductions in beta-amyloid concentrations in vivo by the gamma-secretase inhibitors BMS289948 and BMS-299897. Biochem Pharmacol, 2005, 69:689-698.

共引文献1270

同被引文献227

引证文献13

二级引证文献71

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部